Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Jun 12;14(6):e081947.
doi: 10.1136/bmjopen-2023-081947.

TWINGEN: protocol for an observational clinical biobank recall and biomarker cohort study to identify Finnish individuals with high risk of Alzheimer's disease

Eero Vuoksimaa #  1 , Toni T Saari #  2 , Aino Aaltonen  1 , Sari Aaltonen  1 , Sanna-Kaisa Herukka  3   4 , Paula Iso-Markku  1 , Tarja Kokkola  3 , Aija Kyttälä  5 , Sari Kärkkäinen  3 , Hilkka Liedes  1   6 , Miina Ollikainen  1   7 , Teemu Palviainen  1 , Ilona Ruotsalainen  1   8 , Auli Toivola  5 , Mia Urjansson  1 , Tommi Vasankari  9   10 , Henri Vähä-Ypyä  9 , Markus M Forsberg  11   12 , Mikko Hiltunen  3 , Anu Jalanko  1 , Reetta Kälviäinen  3   4 , Teijo Kuopio  13 , Jaakko Lähteenmäki  8 , Pia Nyberg  14   15 , Minna Männikkö  16 , Raisa Serpi  14 , Sanna Siltanen  17 , Aarno Palotie  1   18   19 , Jaakko Kaprio  1 , Heiko Runz  1   20 , Valtteri Julkunen  3   4 ; FinnGen
Collaborators, Affiliations
Observational Study

TWINGEN: protocol for an observational clinical biobank recall and biomarker cohort study to identify Finnish individuals with high risk of Alzheimer's disease

Eero Vuoksimaa et al. BMJ Open. .

Abstract

Introduction: A better understanding of the earliest stages of Alzheimer's disease (AD) could expedite the development or administration of treatments. Large population biobanks hold the promise to identify individuals at an elevated risk of AD and related dementias based on health registry information. Here, we establish the protocol for an observational clinical recall and biomarker study called TWINGEN with the aim to identify individuals at high risk of AD by assessing cognition, health and AD-related biomarkers. Suitable candidates were identified and invited to participate in the new study among THL Biobank donors according to TWINGEN study criteria.

Methods and analysis: A multi-centre study (n=800) to obtain blood-based biomarkers, telephone-administered and web-based memory and cognitive parameters, questionnaire information on lifestyle, health and psychological factors, and accelerometer data for measures of physical activity, sedentary behaviour and sleep. A subcohort is being asked to participate in an in-person neuropsychological assessment (n=200) and wear an Oura ring (n=50). All participants in the TWINGEN study have genome-wide genotyping data and up to 48 years of follow-up data from the population-based older Finnish Twin Cohort (FTC) study of the University of Helsinki. The data collected in TWINGEN will be returned to THL Biobank from where it can later be requested for other biobank studies such as FinnGen that supported TWINGEN.

Ethics and dissemination: This recall study consists of FTC/THL Biobank/FinnGen participants whose data were acquired in accordance with the Finnish Biobank Act. The recruitment protocols followed the biobank protocols approved by Finnish Medicines Agency. The TWINGEN study plan was approved by the Ethics Committee of Hospital District of Helsinki and Uusimaa (number 16831/2022). THL Biobank approved the research plan with the permission no: THLBB2022_83.

Keywords: Dementia; GENETICS; Observational Study.

PubMed Disclaimer

Conflict of interest statement

Competing interests: AP is the Chief Scientific Officer of the FinnGen project that is funded by 13 pharmaceutical companies. HR was a full-time employee of Biogen during study planning and manuscript drafting and has stocks at Merck & Co and Biogen. MMF has received development funding from the Regional Council of Northern Savo and Business Finland for a data-driven tool related to memory disorders and healthcare decision tools, Charles River DRS Finland Ltd. and Orion Pharma have donated equipment for nonclinical cognition testing at the University of Eastern Finland. PI-M has received funding from Orion Research Foundation and Helsinki Biomedicum Foundation outside the present work. RK declares funding paid to the institution from Academy of Finland, 27 Government research funding, Saastamoinen Foundation, Vaajasalo foundation and Jane and Aatos Erkko foundation outside the present work; consulting fees from Orion Pharma; payment or honoraria from Angelini Pharma, Jazz Pharma, Lundbeck, Eisai, Orion Pharma, OmaMedical, Takeda, UCB; participation in monitoring or advisory board from Marinus Pharma and UCB; and leadership or fiduciary role in European Academy of Neurology Epilepsy scientific panel management group, European Epilepsy Reference network Epicare Steering Group and International League Against Epilepsy Career Development Commission. RS declares stocks or stock options at Orion Pharma. S-KH declares payment or honoraria and support for attending meetings or travel from Roche, consulting fees and participation in monitoring or advisory board from Novartis. TK declares payment or honoraria from Novartis Finland and Bayer Nordic SE. The authors declare no other competing financial or non-financial Interests.

Figures

Figure 1
Figure 1
Flowchart of study participant selection. EH-Epi, Essential Hypertension EPIgenetics.
See this image and copyright information in PMC

Update of

References

    1. Nichols E, Szoeke CEI, Vollset SE, et al. . Global, regional, and national burden of Alzheimer’s disease and other Dementias, 1990–2016: a systematic analysis for the global burden of disease study 2016. The Lancet Neurology 2019;18:88–106. 10.1016/S1474-4422(18)30403-4 - DOI - PMC - PubMed
    1. Prince M, Bryce R, Albanese E, et al. . The global prevalence of dementia: A systematic review and Metaanalysis. Alzheimers Dement 2013;9:63–75. 10.1016/j.jalz.2012.11.007 - DOI - PubMed
    1. Official Statistics of Finland (OSF) . Causes of death. Helsinki: Statistics Finland; 2023. Available: https://www.stat.fi/en/statistics/ksyyt [Accessed 29 Sep 2023].
    1. Malzbender K, Lavin-Mena L, Hughes L, et al. . USC Schaeffer Center for Health Policy and Economics; Key Barriers to Clinical Trials for Alzheimer’s Disease, 2020. Available: https://healthpolicy.usc.edu/research/key-barriers-for-clinical-trialsfo...
    1. Jack CR, Bennett DA, Blennow K, et al. . NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement 2018;14:535–62. 10.1016/j.jalz.2018.02.018 - DOI - PMC - PubMed

Publication types

LinkOut - more resources